US › Healthcare

Instil Bio Inc. (TIL)

US · Healthcare · Biotechnology

$7.21+0.42%

Last close · 2026-09-17

Latest quarter · ended 2026-06-30

Revenue

Net profit

$-4.3M

EPS

$-0.63

EPS estimate

$-0.35

EPS came in at -0.63 against a street estimate of -0.35 — a miss of 80.0%.

Key statistics

Market cap

$48.7M

Forward P/E

0.0

P/B

0.46

Book value

$16.32

EPS (TTM)

$-4.42

52-week high

$21.98

52-week low

$5.67

50-day MA

$7.46

200-day MA

$8.30

Beta

1.92

Analyst view

Analysts rate Instil Bio Inc. a buy (3 buy, 1 hold, 0 sell out of 4) with an average price target of $7.00.

Shareholding

Insiders

6.56%

Institutions

62.50%

Largest institutional holders

Fund	Stake
BML Capital Management LLC	9.52%
Cpmg Inc	6.06%
Kalehua Capital Management LLC	4.76%
Vivo Capital, LLC	4.32%
Vanguard Capital Management, LLC	2.57%
Millennium Management LLC	1.98%
Renaissance Technologies Corp	0.87%
BlackRock Inc	0.77%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Instil Bio Inc. — free to start.

Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc Merck & Company Inc UnitedHealth Group Incorporated Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Amgen Inc Novo Nordisk A/S Gilead Sciences Inc Abbott Laboratories

Data updated 2026-09-18.